Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis
- 1 August 1996
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 105 (2), 249-255
- https://doi.org/10.1016/0304-3835(96)04292-9
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Protection against sr 4233 (tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tironInternational Journal of Radiation Oncology*Biology*Physics, 1994
- SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cellsCancer Letters, 1994
- Muscle cramping in phase i clinical trials of tirapazamine (SR 4233) with and without radiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- The effect of low ph and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitroInternational Journal of Radiation Oncology*Biology*Physics, 1994
- SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumoursBritish Journal of Cancer, 1993
- Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075)Radiotherapy and Oncology, 1993
- The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assayInternational Journal of Radiation Oncology*Biology*Physics, 1989
- SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cellsInternational Journal of Radiation Oncology*Biology*Physics, 1986
- DNA Synthesis and Cell Survival after X-irradiation of Mammalian Cells Treated with Caffeine or AdenineInternational Journal of Radiation Biology, 1978
- DNA Repair in Chinese Hamster Cells of Different Sensitivities to Ultra-violet LightInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1969